Partner With Us NRI

Marksans Pharma Ltd share Price Today

Company details

6M Return 3.67%
1Y Return 73.77%
Mkt Cap.(Cr) 7,476.75
Volume 1,389,465
Div Yield 0.36%
OI Chg %
Volume 1,389,465

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Marksans Pharma announced Q4FY24 & FY24 results:

Q4FY24 Financial Highlights:

  • Operating revenue was Rs 560.0 crore, up by 15.2% YoY driven by by volume gains, new launches, addition of new customers, and increase in our share with existing customers
  • Gross profit was Rs 290.2 crore, up by 19.8% YoY with a Gross margin of 51.8%
  • EBITDA was Rs 109.6 crore, grew by 0.1% with an EBITDA margin of 19.6%
  • EPS was at Rs 1.73 

FY24 Financial Highlights:

  • Operating revenue was Rs 2,177.4 crore, up by 17.6% YoY
  • US and North America business grew by 18.5% YoY
  • UK and Europe grew by 22.9% YoY
  • Gross profit was Rs 1,139.3 crore, up by 22.4% YoY with a Gross margin of 52.3%.
  • EBITDA was Rs 458.6 crore, grew by 35.1% with an EBITDA margin of 21.1%
  • EPS grew by 8.0% YoY to Rs 6.92

Mark Saldanha, Managing Director of the Company said “We are delighted to report a strong performance in FY24 in terms of both revenue and profitability. Our operating revenue for the year grew year-on-year by 18% and EBITDA increased by 35%, supported by new product launches, increase in market share, reduction in raw material prices and operating leverage. This year we have not only met but exceeded our revenue target of Rs 2,000 crore.

We remain confident on delivering sustained long-term value for our shareholders, as we position ourselves strongly in terms of infrastructure, product mix and long-term customer relationships.”

Result PDF

View Other Company Results

Marksans Pharma Ltd shares SWOT Analysis

Strengths (6)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Company with Low Debt
  • Annual Net Profits improving for last 2 years

Weakness (3)

  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Declining profits every quarter for the past 2 quarters
  • Declining Net Cash Flow : Companies not able to generate net cash

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 167.6
R2 170.2
R3 173.9


S1 161.3
S2 157.6
S3 155.0
Delivery and volume
MASSACHUSETTS INSTITUTE OF TECHNOLOGY Bulk Purchase 2024-04-15 158 6600000 NSE
GRAVITON RESEARCH CAPITAL LLP Bulk Purchase 2021-06-15 93.18 3004279 NSE
CRONY VYAPAR PVT LTD Bulk Purchase 2021-06-15 93.75 2900172 NSE
Name Category Shares


Operating Profit
Profit after Tax
Reserves and Surplus
Operating Profit
Profit after Tax

Marksans Pharma Ltd Stocks COMPARISON

Financials( in Cr) Marksans Pharma Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 164.99 1,494.50 1,504.40 4,519.55 1,080.35
% Change 1.38 1.86 -2.41 -0.06 -0.43
Mcap Cr 7,476.75 358,580.62 121,460.29 119,980.04 108,708.49
Revenue TTM Cr 1,852.14 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 265.32 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 23.84 35.84 28.50 74.97 28.20
1 Year Return 73.77 50.67 49.11 28.78 92.89
ROCE 21.77 16.79 14.76 19.30 16.25
ROE 18.00 16.46 10.66 14.89 14.05

Equity Capital: 1,745.17 Cr FV: 1.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 34,603.75 11,365.18
LAST 3M 103,254.09 -13,985.70
LAST 6M 182,650.74 -3,739.19
LAST 12M 295,819.56 101,589.49

Marksans Pharma Ltd Information

Stock PE (TTM)
Promoter Holding
Book Value
  • Marksans Pharma Limited is a pharmaceutical company and has a market capitalization of Rs. 2,916 crores as of 18th August 2021. The company started on 16th April 1992. The company has reported a total quarterly income of Rs.354.84 crores at the end of June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 524404 and scrip code MARKSANS. As of 18th August 2021, Marksans Pharma’s shares were trading at Rs. 71.25.

    The corporate is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company’s research and development centres are in Verna Goa and Navi Mumbai, respectively. With three manufacturing facilities in India, UK, and therefore the US, Marksans has established an authoritative position in regulated markets in India and abroad. The company currently has approximately 1200 employees globally with more than 500 registered products. It also has 50+ experienced scientists in the R& D facility. The promoter holding stood at 48.25% in June 2021 and has remained constant over the last 15 months. Promoters have zero pledged holdings.

    In June 2021, the company reported total revenue of Rs. 354.84 crores as compared to Rs. 336.21 crores during the quarter ended March 2021. It had posted net profit / (loss) of Rs. 62.60 crores for the period ended June 2021 as compared to net profit / (loss) of Rs.79.49 crores for the period ended 31st March 2021. The company’s EPS was at Rs.1.51 for the period ended 30th June '2021, as against Rs.1.93 for the period ended 31st March '2021. On a year-on-year basis, the total income of the company has increased 7.10% from Rs. 331.33 crores to Rs. 354.84 crores with the net profit increasing 26.82% from Rs. 49.36 crores to Rs. 62.60 crores and with EPS increasing 25.83% to Rs. 1.51 as against Rs. 1.2 in June 2020. Over the last 5 years, the company’s market share has increased from 0.49% to 0.54%. Marksans Pharma’s shares closed at Rs. 71.25 (NSE) as of 18th August 2021 and has given a return of 30.38% over the last 12 months.


Registered Address

11th Flr GRANDEUR Oshiwara, Veera Desai Extn Rd Andheri(W), Mumbai, Maharashtra, 400053

Tel : 91-22-40012000
Email : companysecretary:marksanspharma.com ; info:marksan
Website : http://www.marksanspharma.com

Bigshare Services Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 1
Market Lot Equity Shares : 1
BSE Code : 524404
Book Closure Date (Month) :
BSE Group : A
ISIN : INE750C01026

FAQ’s on Marksans Pharma Ltd Shares

You can buy Marksans Pharma Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Marksans Pharma Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 24, 2024 03:59 PM the closing price of Marksans Pharma Ltd was Rs.164.99.

The latest PE ratio of Marksans Pharma Ltd as of Jun 24, 2024 03:59 PM is 23.84

The latest PB ratio of Marksans Pharma Ltd as of Jun 24, 2024 03:59 PM is 0.28

The 52-week high of Marksans Pharma Ltd share price is Rs. 185.50 while the 52-week low is Rs. 90.15

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 24, 2024 03:59 PM, the market cap of Marksans Pharma Ltd stood at Rs. 7,476.75 Cr.

Download App

Download Our App

Play Store App Store
market app